Evidence map›Paper›PMID 41243873›Full record

ArticleMycoses2025

In Vitro Activity of Nitroxoline (5-Nitro-8-Hydroxyquinoline) Against Aspergillus Species.

Ada Hoffmann, Oliver A Cornely, Jana Vonhoegen, Rosanne Sprute, Ilana Reinhold, Grit Walther, Frieder Fuchs, Michaela Simon

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Mycoses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Nitroxoline exerts potent anti-Antimicrobial agents and chemotherapy · 2026
    Article
  3. The therapeutic effect of 5-nitro-8-hydroxyquinoline onFrontiers in cellular and infection microbiology · 2026
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ada HoffmannInstitute for Medical Microbiology, Immunology and Hygiene (IMMIH), Medical Faculty and University Hospital of Cologne, University of Cologne, Cologne, Germany.ORCID https://orcid.org/0000-0002-3093-8417
Oliver A CornelyFaculty of Medicine and University Hospital Cologne, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.ORCID https://orcid.org/0000-0001-9599-3137
Jana VonhoegenInstitute for Medical Microbiology, Immunology and Hygiene (IMMIH), Medical Faculty and University Hospital of Cologne, University of Cologne, Cologne, Germany.ORCID https://orcid.org/0009-0000-9444-278X
Rosanne SpruteFaculty of Medicine and University Hospital Cologne, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.ORCID https://orcid.org/0000-0003-2457-6437
Ilana ReinholdFaculty of Medicine and University Hospital Cologne, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.ORCID https://orcid.org/0000-0002-6222-0418
Grit WaltherNational Reference Center for Invasive Fungal Infections, Leibniz Institute for Natural Product Research and Infection Biology-Hans Knoell Institute, Jena, Germany.ORCID https://orcid.org/0000-0003-4030-4618
Frieder FuchsInstitute for Medical Microbiology, Immunology and Hygiene (IMMIH), Medical Faculty and University Hospital of Cologne, University of Cologne, Cologne, Germany.ORCID https://orcid.org/0000-0001-7075-5378
Michaela SimonInstitute for Medical Microbiology, Immunology and Hygiene (IMMIH), Medical Faculty and University Hospital of Cologne, University of Cologne, Cologne, Germany.ORCID https://orcid.org/0000-0002-8166-7178

Funding

Ministerium für Kultur und Wissenschaft des Landes Nordrhein-WestfalenRobert Koch Institut
6 · The paper itself

Abstract

backgroundNitroxoline is an old antibiotic currently approved for the treatment of uncomplicated urinary tract infections. Its mode of action is based on the chelation of bivalent cations, such as zinc.

objectivesAs zinc plays a central role in the metabolism of Aspergillus spp., we performed antifungal susceptibility testing against Nitroxoline using broth microdilution.

methodsOverall, 13 Aspergillus isolates were tested according to the EUCAST guidance document (Guinea et al. EUCAST, def. doc. 9.4, 2022) including two genetically proven Azole-resistant strains.

resultsThe overall Minimal Inhibitory Concentration (MIC)

conclusionsThese results correspond to excellent in vitro activity against Aspergillus spp.

Indexed as

Antifungal AgentsAspergillusNitroquinolinesAspergillosisDrug Resistance, FungalHumansMicrobial Sensitivity TestsZincAntifungal AgentsNitroquinolinesnitroxolineZincAspergillusazole‐resistancedrug repurposingNitroxoline

Identifiers

PMID41243873
PMCPMC12621168

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.